To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
A Retrospective Real-world Study in Patients With Nasopharyngeal Carcinoma: to Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
1 other identifier
observational
471
1 country
1
Brief Summary
This is a retrospective real-world study to evaluate the efficacy and feasibility of modified reduce-volume target IMRT in the treatment of patients with non-metastatic NPC
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 10, 2020
CompletedFirst Posted
Study publicly available on registry
May 13, 2020
CompletedStudy Start
First participant enrolled
June 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2020
CompletedOctober 9, 2020
October 1, 2020
2 months
May 10, 2020
October 7, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Local failure-free survival (LFFS)
The duration of time to LFFS was calculated from the date of histological diagnosis until documented treatment local failure.
60 month
Study Arms (1)
Modified reduce-volume target IMRT
Patients with newly diagnosed, non-metastatic NPC was given modified reduce-volume target IMRT
Interventions
The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
Eligibility Criteria
Non-metastatic NPC patients treated with modified reduce-volume target IMRT in our institution
You may qualify if:
- Pathologic diagnosis (pathologically confirmed by nasopharyngeal biopsy) was nasopharyngeal carcinoma;
- Newly diagnosed, non-metastatic and treated with modified reduce-volume IMRT;
- Patients with baseline MRI date of nasopharynx and neck, and completed the first course of treatment in our hospital;
- Diagnosis time: November 1, 2014 to December 31 , 2017
You may not qualify if:
- Disease progression during IMRT;
- Previous malignancy or other concomitant malignant diseases;
- The evaluation information of tumor efficacy can not be obtained;
- Receive blind treatment in other clinical research.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of radiation oncology, Fujian cancer hospital
Fuzhou, Fujian, 350014, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 10, 2020
First Posted
May 13, 2020
Study Start
June 1, 2020
Primary Completion
August 1, 2020
Study Completion
October 1, 2020
Last Updated
October 9, 2020
Record last verified: 2020-10